Stocktoria
Vistagen Therapeutics, Inc. VTGN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2010-10-18
Vistagen Therapeutics, Inc. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $486,000 | $1.1M | -$227,000 | $1.1M | $1.1M | $0 | — | $0 | $1.2M |
| R&D expense | $55.0M | $39.4M | $20.0M | $44.4M | $35.4M | $11.9M | $13.4M | $17.1M | $7.8M | $5.2M |
| Operating income | -$72.1M | -$56.0M | -$33.0M | -$59.3M | -$47.8M | -$17.9M | -$20.8M | -$24.6M | -$14.2M | -$10.2M |
| Interest expense | — | — | — | — | — | — | — | $8,000 | $8,900 | $4,600 |
| Income tax | $7,000 | $7,000 | $4,000 | $6,000 | $3,400 | $2,600 | $2,600 | $2,600 | $2,400 | $2,400 |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M | -$47.8M | -$17.9M | -$20.8M | -$24.6M | -$14.3M | -$10.3M |
| EPS (diluted) | $-1.83 | $-1.67 | $-1.52 | $-8.51 | — | — | — | — | — | — |
| Operating cash flow | -$66.4M | -$42.1M | -$25.8M | -$49.7M | -$45.3M | -$12.1M | -$15.8M | -$14.5M | -$9.1M | -$7.3M |
| Free cash flow | — | — | — | — | -$45.5M | -$12.3M | -$15.8M | -$14.7M | -$9.1M | -$7.5M |
| Cash & equivalents | $30.8M | $67.1M | $119.2M | $16.6M | $68.1M | $103.1M | $1.4M | $13.1M | $10.4M | $2.9M |
| Total assets | $48.6M | $84.3M | $123.7M | $21.1M | $74.6M | $108.3M | $5.8M | $14.0M | $11.3M | $3.7M |
| Total liabilities | $13.0M | $14.0M | $9.4M | $9.0M | $9.9M | $16.3M | $11.5M | $6.9M | $4.4M | $3.1M |
| Shareholders' equity | $35.5M | $70.4M | $114.3M | $12.1M | $64.7M | $92.0M | -$5.7M | $7.1M | $6.9M | $615,800 |
Growth · year-over-year · Revenue CAGR 0.2%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +161.1% | -54.3% | — | -120.5% | +1.8% | — | — | — | -100.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.